Oncolytics Biotech INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Oncolytics Biotech reported increased operating expenses and a widening net loss for the six months ended June 30, 2026, while highlighting substantial doubt about its ability to continue as a going concern.
NASDAQ
Oncolytics Biotech reported a net loss of $9.24 million for Q1 2026, with significant increases in R&D and G&A expenses, while cash reserves remain a concern for long-term operations.